Want to see OM full AI Analyst Report?
OM Stock Chart & Stats
$4.25
$0.28(6.93%)
At close: 4:00 PM EDT
$4.25
$0.28(6.93%)
Day’s Range― - ―
52-Week Range$2.84 - $15.94
Previous Close$4.32
Volume70.14K
Average Volume (3M)178.75K
Market Cap
$73.98M
Enterprise Value$37.69M
Total Cash (Recent Filing)$147.19M
Total Debt (Recent Filing)$104.45M
Price to Earnings (P/E)―
Beta2.06
Next Earnings
Nov 10, 2026EPS Estimate
-0.69Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.09
Shares Outstanding18,797,165
10 Day Avg. Volume133,882
30 Day Avg. Volume178,753
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.44
Price to Sales (P/S)0.47
P/FCF Ratio-1.20
Enterprise Value/Market Cap0.51
Enterprise Value/Revenue0.32
Enterprise Value/Gross Profit0.77
Enterprise Value/Ebitda-0.66
Forecast
1Y Price Target
$7.67Price Target Upside80.39% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-3.09
Revenue Forecast (FY)$125.97M
Bulls Say, Bears Say
Bulls Say
Gross Margin ExpansionImproving gross margins indicate better product economics, cost control, and service efficiency. If sustained, this provides greater contribution from each dollar of revenue and supports a credible path toward profitability as Tablo placements and recurring usage scale.
Contracted HCA Refresh BacklogThe HCA agreement strengthens commercial visibility beyond a single quarter and supports replacement demand for the installed Tablo base. Its extension through 2028 can reinforce customer relationships, create recurring treatment opportunities, and validate the platform with a major health system.
Balance Sheet RepairThe sharp reduction in debt materially improves financial flexibility and lowers interest and refinancing pressure relative to prior years. A stronger balance sheet gives Outset more capacity to fund commercialization and product development while it works toward sustainable earnings.
Bears Say
Persistent Losses And Cash BurnOutset remains substantially unprofitable and consumes significant cash despite year-over-year improvement. Continued losses can reduce financial flexibility and may require reliance on existing liquidity or future financing if revenue growth and margin gains do not advance quickly enough.
Consumables And Recurring Revenue SoftnessConsumables are central to the installed-base monetization model, so declining consumable revenue weakens the annuity-like economics expected after system placement. Persistent softness could limit revenue quality, delay operating leverage, and make growth more dependent on capital equipment sales.
Capital Sales Timing VariabilityUnpredictable timing between console commitments, installations, and treatment utilization makes revenue and recurring pull-through harder to forecast. This variability can create uneven quarterly execution, complicate resource planning, and delay the point at which installed systems contribute their full economics.
Outset Medical News
OM FAQ
What was Outset Medical’s price range in the past 12 months?
Outset Medical lowest stock price was $2.84 and its highest was $15.94 in the past 12 months.
What is Outset Medical’s market cap?
Outset Medical’s market cap is $73.98M.
When is Outset Medical’s upcoming earnings report date?
Outset Medical’s upcoming earnings report date is Nov 10, 2026 which is in 21 days.
How were Outset Medical’s earnings last quarter?
Outset Medical released its earnings results on Aug 06, 2026. The company reported -$0.8 earnings per share for the quarter, missing the consensus estimate of -$0.717 by -$0.083.
Is Outset Medical overvalued?
According to Wall Street analysts Outset Medical’s price is currently Undervalued.
Does Outset Medical pay dividends?
Outset Medical does not currently pay dividends.
What is Outset Medical’s EPS estimate?
Outset Medical’s EPS estimate is -0.69.
How many shares outstanding does Outset Medical have?
Outset Medical has 18,797,165 shares outstanding.
What happened to Outset Medical’s price movement after its last earnings report?
Outset Medical reported an EPS of -$0.8 in its last earnings report, missing expectations of -$0.717. Following the earnings report the stock price went down -5.769%.
Which hedge fund is a major shareholder of Outset Medical?
Currently, no hedge funds are holding shares in OM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Outset Medical Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.67 (80.39% Upside)
$7.67 (80.39% Upside)
Blogger Sentiment
Bullish
OM Sentiment 100%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 236.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $823.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 5.1%
Last 30 Days ▼ 5.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-70.44%
12-Months-Change
Fundamentals
Return on Equity
-62.25%
Trailing 12-Months
Asset Growth
-16.07%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Outset Medical
Outset Medical, Inc. is a medical technology firm that specializes in developing hemodialysis systems. The company's primary product is the Tablo Hemodialysis System, a compact console designed to deliver dialysis treatment in various environments, including hospitals and patients' homes. This innovative system boasts integrated water purification, on-demand production of dialysate, and advanced software complete with connectivity features. Founded in 2003, the company initially operated under the name Home Dialysis Plus, Ltd. before rebranding to Outset Medical, Inc. in January 2015. Its corporate headquarters are located in San Jose, California.
OM Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call portrays a predominantly positive commercial and operational trajectory: modest year-over-year revenue growth with strong sequential momentum, meaningful gross margin expansion, a significant $40M refresh agreement with HCA that establishes backlog, a strengthened balance sheet with controlled cash burn, notable implementation and customer success achievements, and an encouraging pilot for next-gen Tablo expected to drive future refresh cycles. Offsetting this optimism are near-term softness in consumables (down 12%), a small decline in product and recurring revenue, continued non-GAAP operating losses, and inherent capital-sales timing variability. On balance, the company communicated improving fundamentals and clear strategic catalysts that outweigh current headwinds.View all OM earnings summariesOM Revenue Breakdown
47.04% Consoles
32.37% Consumables
20.59% Service and other revenue
OM Stock 12 Month Forecast
Average Price Target
$7.67
▲(80.39% Upside)
Technical Analysis
Ownership Overview
20.24% Insiders
21.11% Mutual Funds
1.81% Other Institutional Investors
51.62% Public Companies and
Individual Investors